Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096932 | 0.81 | CA2 (0.45) | CYP11B1CYP11B2NFE2L2MMP2MMP9 | |
| SCHEMBL29271395 | 0.80 | NFE2L2 (0.40) | CYP11B1CYP11B2NFE2L2MMP2MMP9 | |
| SCHEMBL12147832 | 0.78 | TSHR (0.42) | HDAC1 | |
| SCHEMBL30316134 | 0.78 | GABRP (0.52) | — | |
| SCHEMBL29814681 | 0.77 | ALDH1A1 (0.49) | — | |
| SCHEMBL28176537 | 0.77 | CYP11B1 (0.40) | CYP11B1MMP2MMP9MMP8MMP13 | |
| SCHEMBL1697611 | 0.77 | ALDH1A1 (0.49) | — | |
| SCHEMBL2116479 | 0.77 | NFE2L2 (0.38) | CYP11B1CYP11B2NFE2L2MMP2MMP9 | |
| SCHEMBL23114318 | 0.74 | CHRNA7 (0.40) | KCNH2 | |
| SCHEMBL777188 | 0.73 | KMT2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CYP11B1 1179/4885CYP11B2 1298/4885NFE2L2 4335/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CYP11B1 1179/4885CYP11B2 1298/4885NFE2L2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.